ストックスクリーナーアプリを入手
6.38
2.15%
-0.14
アフターアワーズ：
6.36
-0.02
-0.31%
前日終値:
$6.52
開ける：
$6.49
24時間の取引高:
71,717
Relative Volume:
0.70
時価総額：
$46.55M
収益：
-
当期純損益:
$-101.87M
株価収益率:
-5.5478
EPS:
-1.15
ネットキャッシュフロー:
$-83.46M
1週間 パフォーマンス:
-5.48%
1か月 パフォーマンス:
-14.82%
6か月 パフォーマンス:
-3.57%
1年 パフォーマンス:
-24.95%
1日の値動き範囲:
$6.35
$6.75
1週間の範囲:
$6.16
$6.89
52週間の値動き範囲:
$5.202
$11.35
Kezar Life Sciences Inc Stock (KZR) Company Profile
名前
Kezar Life Sciences Inc
セクター
電話
650-822-5600
住所
4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
KZR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KZR
Kezar Life Sciences Inc
|
6.38 | 46.55M | 0 | -101.87M | -83.46M | -1.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kezar Life Sciences Inc Stock (KZR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-08-11 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-03-16 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2018-07-16 | 開始されました | Jefferies | Buy |
| 2018-07-16 | 開始されました | Wells Fargo | Outperform |
| 2018-07-16 | 開始されました | William Blair | Outperform |
すべてを表示
Kezar Life Sciences Inc (KZR) 最新ニュース
Wells Fargo & Company Issues Pessimistic Forecast for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
HC Wainwright Issues Pessimistic Estimate for KZR Earnings - Defense World
Q4 EPS Estimate for Kezar Life Sciences Decreased by Analyst - MarketBeat
Kezar Life Sciences updates shareholder rights agreement - Investing.com
Kezar Life Sciences (NASDAQ:KZR) Given “Neutral” Rating at HC Wainwright - Defense World
William Blair Has Strong Estimate for KZR FY2024 Earnings - MarketBeat
FY2024 Earnings Estimate for KZR Issued By William Blair - Defense World
Kezar Life Sciences (NASDAQ:KZR) and Summit Therapeutics (NASDAQ:SMMT) Head-To-Head Contrast - Defense World
Wells Fargo & Company Has Lowered Expectations for Kezar Life Sciences (NASDAQ:KZR) Stock Price - Defense World
Kezar struck again with second FDA hold - Clinical Trials Arena
Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Kezar Life Sciences (NASDAQ:KZR) Receives "Market Perform" Rating from William Blair - MarketBeat
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
Kezar Life Sciences Reports $20.3M Q3 Loss, Halts Key Lupus Trial Amid Safety Concerns - StockTitan
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR) - Business Wire
Kezar Life Sciences stock hits 52-week high at $7.5 By Investing.com - Investing.com South Africa
Kezar Life Sciences (NASDAQ:KZR) Shares Gap DownHere's What Happened - MarketBeat
Kezar Life Sciences announces 1-for-10 reverse stock split - MSN
Kezar Life Sciences stock hits 52-week high at $7.5 - Investing.com
Kezar Life Sciences announces 1-for-10 reverse stock split By Investing.com - Investing.com Canada
Kezar Life Sciences Stock Scheduled to Reverse Split on Wednesday, October 30th (NASDAQ:KZR) - MarketBeat
Kezar Life Sciences to Implement 1-for-10 Reverse Stock Split - Marketscreener.com
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split - BioSpace
Kezar Life Sciences Announces 1-for-10 Reverse Stock Split | KZR Stock News - StockTitan
What Makes Kezar Life Sciences (KZR) a New Buy Stock - MSN
Kezar shares unchanged as takeover bid rejected By Investing.com - Investing.com UK
Kezar Life Sciences discontinues lupus nephritis programme after fatalities - Clinical Trials Arena
Kezar rejects Concentra's acquisition offer, adopts rights plan By Investing.com - Investing.com South Africa
Kezar Life Sciences Announces Positive IDMC Safety Review of PORTOLA Trial of Zetomipzomib in Patients with Autoimmune Hepatitis and Provides PALIZADE Update - BioSpace
Penny Stock Kezar Life Sciences Rejects Acquisition Deal From Concentra Biosciences At $1.10/Share, Shelves Mid-Stage Lupus Nephritis Study - Benzinga
Concentra Biosciences, LLC cancelled the acquisition of Kezar Life Sciences, Inc. from Tang Capital Partners, LP, managed by Tang Capital Management, LLC and others. - Marketscreener.com
Kezar stock falls 11% after board rejects Concentra offer (NASDAQ:KZR) - Seeking Alpha
Kezar discontinues development of zetomipzomib for lupus nephritis (NASDAQ:KZR) - Seeking Alpha
Kezar stock falls 11% after board rejects Concentra offer (update) - MSN
Kezar to discontinue mid-stage trial for lupus treatment - Reuters
Kezar rejects Concentra's acquisition offer, adopts rights plan - Investing.com
Kezar to focus on AIH drug after halting lupus trial - Investing.com
Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan - StockTitan
Short Interest in Kezar Life Sciences, Inc. (NASDAQ:KZR) Increases By 13.6% - MarketBeat
Kezar Life Sciences, Inc. (NASDAQ:KZR) Sees Significant Growth in Short Interest - Defense World
Kezar Life Sciences (NASDAQ:KZR) Given "Neutral" Rating at HC Wainwright - MarketBeat
H.C. Wainwright maintains Neutral rating on Kezar shares amid acquisition bid - Investing.com UK
Concentra Biosciences proposes to buy Kezar Life Sciences - Investing.com India
Concentra Biosciences proposes to buy Kezar Life Sciences By Investing.com - Investing.com Australia
Kezar Confirms Receipt of Unsolicited, Non-Binding Acquisition Proposal - BioSpace
Kezar Life Sciences Inc (KZR) 財務データ
収益
当期純利益
現金流量
EPS
2.88%
2.65%
大文字化:
|
ボリューム (24 時間):